On March 11, 2020, the World Health Organization declared COVID-19 a pandemic — and within days the world did something it had never done in history: it stopped. Borders slammed shut, cities fell silent, and more than half of humanity learned to live behind masks and curfews.
The story in images
The COVID era in images
The great stop
In Spring 2020, lockdowns swept the globe. One week the world was commuting; the next, streets from Milan to New York stood empty, schools closed their doors, and passenger planes sat parked nose-to-tail in desert boneyards. The WHO had said the word — pandemic — on March 11, 2020, and governments reached for a lever no peacetime state had pulled at such scale: telling everyone, at once, to stay home.
The race for a vaccine
Science answered with unnatural speed. In December 2020 the first vaccines were administered — in the United Kingdom on December 8, 2020 — the fastest vaccine rollout in history. What had normally taken a decade had taken a year, and the syringe became the century’s most political object: who got it, in what order, and from whom.
The other business
The vaccines worked. They were also, on paper, worth more than anything the pharmaceutical industry had ever sold. In 2021, Pfizer booked $36.781 billion in revenue from Comirnaty alone — its own annual report says so — and total company revenue reached a record $81.3 billion, up 95% in a single year; the following year it crossed $100 billion. Moderna, a company that had never sold a product in its life, went from $803 million in revenue in 2020 to $18.5 billion in 2021, with a net income of $12.2 billion — and then announced a $3 billion share buyback. These are the companies’ own earnings reports, not estimates.
The money, it is worth noting, arrived before the glory. In July 2020, the U.S. government promised Pfizer $1.95 billion for 100 million doses, then another $2 billion in December 2020 and another $2 billion in February 2021. BioNTech, Pfizer’s partner, received nearly $500 million from the German government. Taxpayers funded the runway; shareholders took the altitude.
Personnel moved between the two worlds as easily as the money did. Moncef Slaoui, the man chosen to run America’s Operation Warp Speed, came off the board of Moderna — while holding Moderna stock options worth roughly $8 to $10 million, a position he divested only under pressure, donating the gains to cancer research. The administration classified him as a contractor, a designation that — as ProPublica documented at the time — meant the usual ethics rules on divestiture did not apply. In Brussels, the largest vaccine deal in European history — up to 1.8 billion Pfizer-BioNTech doses, signed in May 2021 — was negotiated privately by Commission president Ursula von der Leyen over text messages with Pfizer CEO Albert Bourla; when the New York Times asked to see them, the Commission declined, the EU Ombudsman found maladministration, and in May 2025 the EU’s General Court annulled the refusal outright. The contents remain undisclosed to this day.
The human cost of the pandemic deserves gravity: the fear, the closed wards, the empty chairs. This is the other ledger — laid out plainly, because it happened.
Delta, Omicron and the long tail
2021 belonged to the variants. The Delta and Omicron waves ran through 2021, each redrawing the map of risk and dragging restrictions back into countries that had believed the pandemic was over. The virus kept mutating; the world kept reopening and reclosing, learning that immunity and politics move at different speeds.
The whiplash economy
Economies cratered, then roared back with inflation. The shutdowns produced some of the sharpest recessions in generations — and the reopening produced some of the sharpest price surges, as stimulus met broken supply chains and suddenly released demand. Central banks, first in full support mode, then in full retreat, discovered that restarting the machine costs more than stopping it.
The pivot
By early 2022, the world’s attention was moving on. When Russia invaded Ukraine on February 24, 2022, the planet’s gaze swung eastward — not because the pandemic had ended, but because the century had served up a new emergency. The COVID era did not die that day; it simply ceased to be the story the world was watching.
The COVID era rewrote the relationship between the state and the citizen — and between the economy and the virus. It proved how quickly billions of people could change their behavior, how fragile just-in-time globalization was, and how fast a laboratory could answer when the whole world was waiting. It also bequeathed the inflation of the decade that followed, and a generation that had learned the hardest lesson of all: normal is negotiable.